Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Conditioning Regimens

Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS

Bone Marrow Transplantation volume 47, pages 203–211 (2012)Cite this article

Abstract

Although reduced-intensity conditioning (RIC) and non-myeloablative (NMA)-conditioning regimens have been used for over a decade, their relative efficacy vs myeloablative (MA) approaches to allogeneic hematopoietic cell transplantation in patients with AML and myelodysplasia (MDS) is unknown. We compared disease status, donor, graft and recipient characteristics with outcomes of 3731 MA with 1448 RIC/NMA procedures performed at 217 centers between 1997 and 2004. The 5-year univariate probabilities and multivariate relative risk outcomes of relapse, TRM, disease-free survival (DFS) and OS are reported. Adjusted OS at 5 years was 34, 33 and 26% for MA, RIC and NMA transplants, respectively. NMA conditioning resulted in inferior DFS and OS, but there was no difference in DFS and OS between RIC and MA regimens. Late TRM negates early decreases in toxicity with RIC and NMA regimens. Our data suggest that higher regimen intensity may contribute to optimal survival in patients with AML/MDS, suggesting roles for both regimen intensity and graft vs leukemia in these diseases. Prospective studies comparing regimens are needed to confirm this finding and determine the optimal approach to patients who are eligible for either MA or RIC/NMA conditioning.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3

Similar content being viewed by others

References

  1. Vicente D, Lamparelli T, Gualandi F, Occhini D, Raiola AM, Ibatici A et al. Improved outcome in young adults with de novo acute myeloid leukemia in first remission, undergoing an allogeneic bone marrow transplant. Bone Marrow Transplant 2007; 40: 349–354.

    Article  CAS  PubMed  Google Scholar 

  2. Blaise D, Maraninchi D, Archimbaud E, Reiffers J, Devergie A, Jouet JP et al. Allogeneic bone marrow transplantation for acute myeloid leukemia in first remission: a randomized trial of a busulfan-cytoxan versus cytoxan-total body irradiation as preparative regimen: a report from the Group d’Etudes de la Greffe de Moelle Osseuse. Blood 1992; 79: 2578–2582.

    CAS  PubMed  Google Scholar 

  3. Chang C, Storer BE, Scott BL, Bryant EM, Shulman HM, Flowers ME et al. Hematopoietic cell transplantation in patients with myelodysplastic syndrome or acute myeloid leukemia arising from myelodysplastic syndrome: similar outcomes in patients with de novo disease and disease following prior therapy or antecedent hematologic disorders. Blood 2007; 110: 1379–1387.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Slavin S, Nagler A, Naparstek E, Kapelushnik Y, Aker M, Cividalli G et al. Nonmyeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. Blood 1998; 91: 756–763.

    CAS  PubMed  Google Scholar 

  5. McSweeney PA, Niederwieser D, Shizuru JA, Sandmaier BM, Molina AJ, Maloney DG et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood 2001; 97: 3390–3400.

    Article  CAS  PubMed  Google Scholar 

  6. Giralt S, Estey E, Albitar M, van Besien K, Rondon G, Anderlini P et al. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy. Blood 1997; 89: 4531–4536.

    CAS  PubMed  Google Scholar 

  7. Khouri IF, Keating M, Korbling M, Przepiorka D, Anderlini P, O′Brien S et al. Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies. J Clin Oncol 1998; 16: 2817–2824.

    Article  CAS  PubMed  Google Scholar 

  8. Hegenbart U, Niederwieser D, Sandmaier BM, Maris MB, Shizuru JA, Greinix H et al. Treatment for acute myelogenous leukemia by low-dose, total-body, irradiation-based conditioning and hematopoietic cell transplantation from related and unrelated donors. J Clin Oncol 2006; 24: 444–453.

    Article  CAS  PubMed  Google Scholar 

  9. Gratwohl A, Baldomero H, Frauendorfer K, Urbano-Ispizua A . EBMT activity survey 2004 and changes in disease indication over the past 15 years. Bone Marrow Transplant 2006; 37: 1069–1085.

    Article  CAS  PubMed  Google Scholar 

  10. Bertz H, Potthoff K, Finke J . Allogeneic stem-cell transplantation from related and unrelated donors in older patients with myeloid leukemia. J Clin Oncol 2003; 21: 1480–1484.

    Article  PubMed  Google Scholar 

  11. Martino R, Caballero MD, Perez-Simon JA, Canals C, Solano C, Urbano-Ispizua A et al. Evidence for a graft-versus-leukemia effect after allogeneic peripheral blood stem cell transplantation with reduced-intensity conditioning in acute myelogenous leukemia and myelodysplastic syndromes. Blood 2002; 100: 2243–2245.

    Article  CAS  PubMed  Google Scholar 

  12. Tauro S, Craddock C, Peggs K, Begum G, Mahendra P, Cook G et al. Allogeneic stem-cell transplantation using a reduced-intensity conditioning regimen has the capacity to produce durable remissions and long-term disease-free survival in patients with high-risk acute myeloid leukemia and myelodysplasia. J Clin Oncol 2005; 23: 9387–9393.

    Article  CAS  PubMed  Google Scholar 

  13. Mohty M, Bay JO, Faucher C, Choufi B, Bilger K, Tournilhac O et al. Graft-versus-host disease following allogeneic transplantation from HLA-identical sibling with antithymocyte globulin-based reduced-intensity preparative regimen. Blood 2003; 102: 470–476.

    Article  CAS  PubMed  Google Scholar 

  14. Niederwieser D, Maris M, Shizuru JA, Petersdorf E, Hegenbart U, Sandmaier BM et al. Low-dose total body irradiation (TBI) and fludarabine followed by hematopoietic cell transplantation (HCT) from HLA-matched or mismatched unrelated donors and postgrafting immunosuppression with cyclosporine and mycophenolate mofetil (MMF) can induce durable complete chimerism and sustained remissions in patients with hematological diseases. Blood 2003; 101: 1620–1629.

    Article  CAS  PubMed  Google Scholar 

  15. Flynn CM, Hirsch B, Defor T, Barker JN, Miller JS, Wagner JE et al. Reduced intensity compared with high dose conditioning for allotransplantation in acute myeloid leukemia and myelodysplastic syndrome: a comparative clinical analysis. Am J Hematol 2007; 82: 867–872.

    Article  PubMed  Google Scholar 

  16. Scott BL, Sandmaier BM, Storer B, Maris MB, Sorror ML, Maloney DG et al. Myeloablative vs nonmyeloablative allogeneic transplantation for patients with myelodysplastic syndrome or acute myelogenous leukemia with multilineage dysplasia: a retrospective analysis. Leukemia 2006; 20: 128–135.

    Article  CAS  PubMed  Google Scholar 

  17. Massenkeil G, Nagy M, Neuburger S, Tamm I, Lutz C, le Coutre P et al. Survival after reduced-intensity conditioning is not inferior to standard high-dose conditioning before allogeneic haematopoietic cell transplantation in acute leukaemias. Bone Marrow Transplant 2005; 36: 683–689.

    Article  CAS  PubMed  Google Scholar 

  18. Alyea EP, Kim HT, Ho V, Cutler C, DeAngelo DJ, Stone R et al. Impact of conditioning regimen intensity on outcome of allogeneic hematopoietic cell transplantation for advanced acute myelogenous leukemia and myelodysplastic syndrome. Biol Blood Marrow Transplant 2006; 12: 1047–1055.

    Article  PubMed  Google Scholar 

  19. Giralt S, Ballen K, Rizzo D, Bacigalupo A, Horowitz M, Pasquini M et al. Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a workshop convened by the center for international blood and marrow transplant research. Biol Blood Marrow Transplant 2009; 15: 367–369.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Giralt S, Logan B, Rizzo D, Zhang MJ, Ballen K, Emmanouilides C et al. Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the national marrow donor program. Biol Blood Marrow Transplant 2007; 13: 844–852.

    Article  PubMed  Google Scholar 

  21. Gooley TA, Leisenring W, Crowley J, Storer BE . Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999; 18: 695–706.

    Article  CAS  PubMed  Google Scholar 

  22. Klein J, Moeschberger M . Survival Analysis: Techniques of Censored and Truncated Data. 2nd edn Springer-Verlag: New York, NY, 2003.

    Google Scholar 

  23. Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia 2005; 19: 2304–2312.

    Article  CAS  PubMed  Google Scholar 

  24. Ringden O, Labopin M, Ehninger G, Niederwieser D, Olsson R, Basara N et al. Reduced intensity conditioning compared with myeloablative conditioning using unrelated donor transplants in patients with acute myeloid leukemia. J Clin Oncol 2009; 27: 4570–4577.

    Article  PubMed  Google Scholar 

  25. Report from the International Bone Marrow Transplant Registry. Advisory committee of the international bone marrow transplant registry. Bone Marrow Transplant 1989; 4: 221–228.

    Google Scholar 

  26. Martino R, Iacobelli S, Brand R, Jansen T, van Biezen A, Finke J et al. Retrospective comparison of reduced-intensity conditioning and conventional high-dose conditioning for allogeneic hematopoietic stem cell transplantation using HLA-identical sibling donors in myelodysplastic syndromes. Blood 2006; 108: 836–846.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

The CIBMTR is supported by Public Health Service Grant/Cooperative Agreement U24-CA76518 from the National Cancer Institute (NCI), the National Heart, Lung and Blood Institute (NHLBI) and the National Institute of Allergy and Infectious Diseases; a grant/cooperative agreement 5U01HL069294 from NHLBI and NCI; a contract HHSH234200637015C with Health Resources and Services Administration (HRSA/DHHS); two grants N00014-06-1-0704 and N00014-08-1-0058 from the Office of Naval Research; grants from AABB; Aetna; American Society for Blood and Marrow Transplantation; Amgen Inc.; anonymous donation to the Medical College of Wisconsin; Astellas Pharma US Inc.; Baxter International Inc.; Bayer HealthCare Pharmaceuticals; Be the Match Foundation; Biogen IDEC; BioMarin Pharmaceutical Inc.; Biovitrum AB; Blood Center of Wisconsin; Blue Cross and Blue Shield Association; Bone Marrow Foundation; Canadian Blood and Marrow Transplant Group; CaridianBCT; Celgene Corporation; CellGenix, GmbH; Centers for Disease Control and Prevention; Children's Leukemia Research Association; ClinImmune Labs; CTI Clinical Trial and Consulting Services; Cubist Pharmaceuticals; Cylex Inc.; CytoTherm; DOR BioPharma Inc.; Dynal Biotech, an Invitrogen Company; Eisai Inc.; Enzon Pharmaceuticals Inc.; European Group for Blood and Marrow Transplantation; Gamida Cell Ltd; GE Healthcare; Genentech Inc.; Genzyme Corporation; Histogenetics Inc.; HKS Medical Information Systems; Hospira Inc.; Infectious Diseases Society of America; Kiadis Pharma; Kirin Brewery Co. Ltd; The Leukemia & Lymphoma Society; Merck & Company; The Medical College of Wisconsin; MGI Pharma Inc.; Michigan Community Blood Centers; Millennium Pharmaceuticals Inc.; Miller Pharmacal Group; Milliman USA Inc.; Miltenyi Biotec Inc.; NMDP; Nature Publishing Group; New York Blood Center; Novartis Oncology; Oncology Nursing Society; Osiris Therapeutics Inc.; Otsuka America Pharmaceutical Inc.; Pall Life Sciences; Pfizer Inc.; Saladax Biomedical Inc.; Schering Corporation; Society for Healthcare Epidemiology of America; StemCyte Inc.; StemSoft Software Inc.; Sysmex America Inc.; Teva Pharmaceutical Industries; Therakos Inc.; Thermogenesis Corporation; Vidacare Corporation; Vion Pharmaceuticals Inc.; ViraCor Laboratories; ViroPharma Inc.; and Wellpoint Inc. The views expressed in this article do not reflect the official policy or position of the National Institute of Health, the Department of the Navy, the Department of Defense or any other agency of the US Government. We thank Karen Ballen, Willem Bujan, Steven Goldstein, Roger Herzig, Osman Ilhan, Luis Isola, Jane Liesveld, Gustavo Milone, David Rizzieri, James Russell, Mitchell Sabloff, Stella Santarone, Gary Schiller, Robert Soiffer, Edmund Waller, Roy Weiner and Peter Wiernik for helpful comments and insights.

Author information

Authors and Affiliations

  1. Abramson Cancer Center, Hospital of the University of Pennsylvania, Philadelphia, PA, USA

    S M Luger

  2. Karolinska University Hospital, Huddinge, Sweden

    O Ringdén

  3. Center for International Blood and Marrow Transplant Research, Medical College of Wisconsin, Milwaukee, WI, USA

    M-J Zhang & W S Pérez

  4. National Cancer Institute, Bethesda, MD, USA

    M R Bishop

  5. Universitatsklinikum Carl Gustav Carus, Dresden, Germany

    M Bornhauser

  6. Froedtert Memorial Lutheran Hospital, Milwaukee, WI, USA

    C N Bredeson

  7. Morgan Stanley Children's Hospital of New York, New York, NY, USA

    M S Cairo

  8. Cleveland Clinic, Taussig Cancer Center, Cleveland, OH, USA

    E A Copelan

  9. Celgene Corporation, Summit, NJ, USA

    R P Gale

  10. MD Anderson Cancer Center, Houston, TX, USA

    S A Giralt

  11. Osman Gazi University Medical School, Eskisehir, Turkey

    Z Gulbas

  12. Princess Margaret Hospital, Toronto, Ontario, Canada

    V Gupta

  13. All Children's Hospital, St. Petersburg, FL, USA

    G A Hale

  14. Case Comprehensive Cancer Center, University Hospitals Case Medical Center, Cleveland, OH, USA

    H M Lazarus

  15. Alberta Children's Hospital, Calgary, Alberta, Canada

    V A Lewis

  16. Cedars Sinai Medical Center, Los Angeles, CA, USA

    M C Lill

  17. Roswell Park Cancer Institute, Buffalo, NY, USA

    P L McCarthy

  18. Masonic Cancer Center, University of Minnesota Medical Center, Minneapolis, MN, USA

    D J Weisdorf

  19. University of Utah Health Science Center, Salt Lake City, UT, USA

    M A Pulsipher

Authors
  1. S M Luger
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. O Ringdén
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M-J Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. W S Pérez
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. M R Bishop
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M Bornhauser
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. C N Bredeson
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. M S Cairo
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. E A Copelan
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. R P Gale
    View author publications

    You can also search for this author in PubMed Google Scholar

  11. S A Giralt
    View author publications

    You can also search for this author in PubMed Google Scholar

  12. Z Gulbas
    View author publications

    You can also search for this author in PubMed Google Scholar

  13. V Gupta
    View author publications

    You can also search for this author in PubMed Google Scholar

  14. G A Hale
    View author publications

    You can also search for this author in PubMed Google Scholar

  15. H M Lazarus
    View author publications

    You can also search for this author in PubMed Google Scholar

  16. V A Lewis
    View author publications

    You can also search for this author in PubMed Google Scholar

  17. M C Lill
    View author publications

    You can also search for this author in PubMed Google Scholar

  18. P L McCarthy
    View author publications

    You can also search for this author in PubMed Google Scholar

  19. D J Weisdorf
    View author publications

    You can also search for this author in PubMed Google Scholar

  20. M A Pulsipher
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to D J Weisdorf.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Luger, S., Ringdén, O., Zhang, MJ. et al. Similar outcomes using myeloablative vs reduced-intensity allogeneic transplant preparative regimens for AML or MDS. Bone Marrow Transplant 47, 203–211 (2012). https://doi.org/10.1038/bmt.2011.69

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/bmt.2011.69

Keywords

This article is cited by

Search

Advanced search

Quick links